Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL

Status Not yet recruiting

Clinical Trial Summary

Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. To make a further improvement, adapting the FasT CAR-T cells manufacture technology to shorten the manufacturing time and maintain the stemness of CAR-T cells. We launch such a clinical trial using CD19 targeted CAR-T cells for patients with relapsed and refractory B-cell NHL to evaluate the efficacy and safety of CD19 targeted CAR-T cell therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Lymphoma, Non-Hodgkin

Clinical Trial Details

NCT number	NCT04638270
Study type	Interventional
Source	Xinqiao Hospital of Chongqing
Contact	Xi Zhang, MD phD
Phone	13808310064
Email	zhangxxi@sina.com
Status	Not yet recruiting
Phase	Early Phase 1
Start date	November 21, 2020
Completion date	November 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05540340` - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant	Phase 1
Recruiting	`NCT04460235` - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma	Phase 4
Completed	`NCT03484702` - Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 2
Completed	`NCT01410630` - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting	`NCT05024045` - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers	Phase 1
Completed	`NCT06190457` - Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
Completed	`NCT02369016` - Phase III Copanlisib in Rituximab-refractory iNHL	Phase 3
Recruiting	`NCT01676805` - Tissue Collection for Studies of Lymph Cancer
Terminated	`NCT00916045` - Pilot Study of Unrelated Cord Blood Transplantation	Phase 2
Terminated	`NCT00529503` - A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL	Phase 2
Completed	`NCT00534989` - Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT	N/A
Withdrawn	`NCT00538096` - A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma	Phase 1
Withdrawn	`NCT00319332` - A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen	Phase 3
Completed	`NCT00156013` - Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)	Phase 1/Phase 2
Completed	`NCT00322842` - Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients	Phase 2
Completed	`NCT00141297` - A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer	Phase 1
Completed	`NCT02509039` - A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)	Phase 1
Completed	`NCT01573000` - A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)	Phase 2
Completed	`NCT00268203` - Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma	Phase 2
Completed	`NCT03289182` - An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)